A carregar...
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was performed to aggregate the mixed results of published clinical trials to assess the efficacy and safety of osimertinib. A system...
Na minha lista:
| Publicado no: | Int J Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590181/ https://ncbi.nlm.nih.gov/pubmed/30613959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32097 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|